
Press release

Collectis bioresearch signs non-exclusive license with Evrogen for access to fluorescent proteins

Paris, December 7, 2010 - Collectis bioresearch, the specialist in genome customization and subsidiary of Collectis (Alternext: ALCLS), today announced that it has signed a non-exclusive agreement with Evrogen (Moscow, Russia) for access to its fluorescent proteins. This license allows Collectis bioresearch to incorporate these proteins into its own products and will expand the company's offering of genome engineering tools.

Luc Selig, Sales and Marketing Director of Collectis bioresearch, commented, "One of the key components of our kits is the integration matrix which enables the user to express a gene of interest. By extending the choice of promoters and tags in these matrices, we can offer our clients a full range of methods to achieve single-phase developments, thus saving valuable time during experiments."

Collectis bioresearch develops and commercializes ready- and easy-to-use tools and technologies for the life science industry. These tools can be used to customize any cell for drug development, protein production or functional genomics. To date, Collectis bioresearch markets over one hundred products through its online store and international distribution network and sales forces.

About Collectis bioresearch

Collectis bioresearch was incorporated as a subsidiary of Collectis (Alternext: ALCLS) in June 2008. It provides life science researchers with ready- and easy-to-use tools for genome customization. These tools, based on meganucleases, enable the engineering of cells with optimized features for drug discovery, protein production and gene functional studies. The kits can be purchased online from www.collectis-bioresearch.com. Check the website for more information.

About Collectis

Collectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools – meganucleases. These molecular scissors enable targeted modifications to DNA, with applications in the research, biomanufacturing, agrobiotechnology and therapeutic sectors. To date, Collectis has formed over 20 academic research partnerships and has established more than 50 agreements with pharmaceutical laboratories, seed producers and biotech companies across the world. The company holds exclusive rights to a portfolio of over 260 patents granted or pending.

Since 2007, Collectis has been listed on the NYSE-Euronext Alternext market (code: ALCLS) in Paris and has secured over €70 million in funding since inception.

More information at www.collectis.com.



About Evrogen

Evrogen is an innovation-driven company founded by scientists and dedicated to making successful ideas widely available as efficient products and services for life science research.

More information at www.evrogen.com.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company's products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company's prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers ("AMF") granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

For further information, please contact:

CELLECTIS

Sylvie Delassus
Senior VP Corporate Communication
+ 33 (0)1 41 83 99 00
media@collectis.com

ALIZE RP

Caroline Carmagnol
+33 (0)6 64 18 99 59
caroline@alizerp.com

Evrogen JCS

Timofei Panfilov
+7 495 988 4083 ext.725
timofei@evrogen.ru